Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.

Daiki TsujiMegumi MatsumotoYohei KawasakiYong-I L KimKeisuke YamamotoHidenori NakamichiYuri SaharaRyo MakutaMari YokoiTakehiro MiyagiKunihiko Itoh

Published in: Cancer chemotherapy and pharmacology (2020)

No significant association was found between ABCB1 2677G > T/A and CR0-24. However, it was observed that the polymorphism of TACR1, which encodes the neurokinin 1 receptor, might be a potential genetic risk factor for the development of delayed phase CINV.

Keyphrases

chemotherapy induced
low dose
drug delivery
high dose
genome wide
clinical decision support
cancer therapy
copy number
gene expression
locally advanced
risk assessment
electronic health record